In terms of QoL, there appear to be slight advantages for nivolumab + cabozantinib among the ICI/VEGFR-TKI combinations; in contrast, pembrolizumab + lenvatinib appears to achieve the highest tumor control (ORR, PFS). This evidence concerns the gene KDR and neoplasm.